Figure 3.
Figure 3. T-cell responses against Bcl-2 as measured by IFN-γ ELISPOT. PBLs from 10 HLA-A2–positive patients with CLL and 3 HLA-A2–positive patients with AML were analyzed. The peptides Bcl208 (A) and Bcl214 (B) were examined. T lymphocytes were stimulated once with peptide before being plated at 105 cells per well in triplicates either without or with peptide. The average number of peptide-specific spots (after subtraction of spots without added peptide) was calculated for each patient using the ImmunoSpot Series 2.0 Analyzer (CTL Analyzers). Responders (defined as average number of antigen-specific spots ± 1/2 standard deviation > 25 per 105 lymphocytes) are marked as , whereas nonresponding individuals are marked as ⋄.

T-cell responses against Bcl-2 as measured by IFN-γ ELISPOT. PBLs from 10 HLA-A2–positive patients with CLL and 3 HLA-A2–positive patients with AML were analyzed. The peptides Bcl208 (A) and Bcl214 (B) were examined. T lymphocytes were stimulated once with peptide before being plated at 105 cells per well in triplicates either without or with peptide. The average number of peptide-specific spots (after subtraction of spots without added peptide) was calculated for each patient using the ImmunoSpot Series 2.0 Analyzer (CTL Analyzers). Responders (defined as average number of antigen-specific spots ± 1/2 standard deviation > 25 per 105 lymphocytes) are marked as , whereas nonresponding individuals are marked as ⋄.

Close Modal

or Create an Account

Close Modal
Close Modal